Abstract: The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.

Abstract: The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.

Abstract: The present invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from inflammatory disease to a treatment with a therapy against said inflammatory disease using brain imaging techniques. Furthermore, the present invention relates to a pharmaceutical composition comprising an active ingredient for the treatment of human subjects suffering from inflammatory disease and being identified as responders to therapy against the inflammatory disease according to the method of the invention. Preferably, this invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from rheumatoid arthritis to a treatment with TNF-antagonists comprising at least one step of brain imaging, preferably with an fMRI apparatus. The present invention shows that response to TNFi depends on the gestalt of brain activity in rheumatoid arthritis (RA) patients.

Abstract: A method of using at least one quantitative ratio of two different amyloid beta-peptides in a sample of a body fluid from a patient for determining the patient's probability of contracting Alzheimer's disease (AD) or for determining the patient's suffering from a precursor of Alzheimer's disease includes obtaining the sample of the body fluid from the patient. The at least one quantitative ratio is calculated from the two different amyloid beta-peptides from the sample. The patient's probability of contracting Alzheimer's disease (AD) or the patient's suffering from a precursor of Alzheimer's disease is calculated using the at least one quantitative ratio. The two different amyloid beta-peptides are selected from (a) A?(1-42), (b) A?(2-40) and (c) A?(2-42). The at least one quantitative ratio is selected from (a) A?(1-42)/(b) A?(2-40), (a) A?(1-42)/(c) A?(2-42), (b) A?(2-40)/(a) A?(1-42) and (c) A?(2-42)/(a) A?(1-42).